

Renata Duchnowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6832237/publications.pdf>

Version: 2024-02-01

9
papers

409
citations

1478505

6
h-index

1588992

8
g-index

11
all docs

11
docs citations

11
times ranked

894
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. <i>Cancers</i> , 2022, 14, 965.	3.7	2
2	The Usefulness of Prognostic Tools in Breast Cancer Patients with Brain Metastases. <i>Cancers</i> , 2022, 14, 1099.	3.7	1
3	Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review. <i>Cancers</i> , 2021, 13, 5306.	3.7	0
4	Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 71-77.	7.7	64
5	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , 2018, 9, 2705.	12.8	91
6	Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5287-5299.	7.0	126
7	Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff. <i>Clinical Cancer Research</i> , 2014, 20, 2805-2813.	7.0	28
8	Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner. <i>Clinical Cancer Research</i> , 2014, 20, 2727-2739.	7.0	57
9	Correlation Between Quantitative HER2 Protein Expression and Risk for Brain Metastases in HER2 + Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. <i>Oncologist</i> , 2012, 17, 26-35.	3.7	39